SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

olevaprubart

IMA·ImageneBio, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2b
Time to market
If the Phase 2b ADAPTIVE trial (topline Q4 2027) succeeds, a Phase 3 program would follow, meaning potential approval is likely several years away, probably no earlier than 2029-2030.
Why 4/10
The next hard, dated catalyst is the Phase 2b ADAPTIVE topline data readout in atopic dermatitis, expected in Q4 2027, which is more than 12 months away. With no nearer binary catalyst, the impact score is capped at 4 despite olevaprubart being the company's sole pipeline asset.
Actionable Insight NEUTRAL

The next hard catalyst is the Phase 2b ADAPTIVE topline readout in atopic dermatitis, expected in Q4 2027, over a year away. In the nearer term, watch for initiation of the Phase 2 alopecia areata study by year-end 2026 and any early efficacy signals. The OX40 competitive landscape is shifting rapidly with Sanofi's amlitelimab setback and AbCellera's exit, which could be a relative positive for olevaprubart's positioning.

Price Chart

Loading chart...

Executive Summary

Olevaprubart (IMG-007) is ImageneBio's sole pipeline asset, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life being developed for atopic dermatitis and alopecia areata. The Phase 2b ADAPTIVE trial in atopic dermatitis is ongoing with topline data expected in Q4 2027, while a Phase 2 alopecia areata study is on track to start by year-end 2026. Phase 2a data showed rapid, durable improvement with a well-tolerated profile. The OX40 competitive landscape is mixed: rocatinlimab (Amgen/Kyowa Kirin) has positive Phase 3 data, but Sanofi abandoned amlitelimab in atopic dermatitis and AbCellera exited the space. With $126.6M cash, no near-term binary catalyst, and a wide analyst target range ($2-$28), the stock ($3.72) reflects deep uncertainty about the drug's prospects until the ADAPTIVE readout in late 2027.

How It Works

Olevaprubart is an antibody that blocks the OX40 receptor on immune T cells. OX40 acts like an 'on' switch for inflammatory T cells that drive diseases like eczema (atopic dermatitis) and alopecia areata (hair loss). By blocking OX40 without killing the T cells (non-T cell-depleting) and with a modified tail that avoids certain immune side effects (ADCC-silenced), the drug aims to calm the overactive immune response. Its extended half-life means patients may need less frequent dosing.

Trial Status

The Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis is actively enrolling in North America under an amended protocol. Topline data is expected in Q4 2027. A Phase 2 study in alopecia areata is on track to initiate by year-end 2026 with initial data expected in 2028. Phase 2a data in both indications have been reported: positive interim results in atopic dermatitis (Jan 2025) and positive topline results in alopecia areata (Apr 2025).

The Two-Sided Case

▲ Bull Case5
Olevaprubart is a potential first-in-class non-T cell-depleting, ADCC-silenced anti-OX40 antagonist with an extended half-life, which could offer a differentiated safety and dosing profile versus competitors like rocatinlimab (T-cell depleting).
Phase 2a data in atopic dermatitis showed rapid, marked, and durable improvement with a well-tolerated profile and no Kaposi sarcoma cases across all trials, addressing a key safety concern for the class.
Sanofi's abandonment of amlitelimab and AbCellera's OX40 exit reduce competitive noise, potentially widening olevaprubart's commercial opportunity if Phase 2b succeeds.
The company has $126.6M in cash providing runway into Q1 2008, and the reduced quarterly net loss ($15.6M in Q3 2026 vs $24.8M in Q3 2025) suggests improved capital efficiency.
Analyst consensus shows 6 Buy/Strong Buy ratings with a mean price target of $18 (vs $3.72 current price), implying significant upside if the drug delivers positive Phase 2b data.
▼ Bear Case5
The Phase 2b ADAPTIVE topline readout is not expected until Q4 2027, leaving the stock without a near-term binary catalyst for over a year, which creates a long period of data-free drift.
The OX40 class is crowded and has seen setbacks: Sanofi abandoned amlitelimab approval efforts in atopic dermatitis (July 2026), and AbCellera exited the space (Nov 2026), raising questions about the commercial viability of the mechanism.
Rocatinlimab (Amgen/Kyowa Kirin) has already reported positive Phase 3 ROCKET data, potentially establishing a competitive benchmark that olevaprubart must match or exceed.
The company is pre-revenue with no approved products, burning ~$15-16M per quarter, and while $126.6M in cash provides runway into Q1 2028, it may need additional capital before reaching the ADAPTIVE readout.
Analyst views are polarized: Wedbush rates the stock Underperform, and the wide price target range ($2 low to $28 high) reflects deep uncertainty about the drug's prospects.

Upcoming Catalysts

  • Initiation of Phase 2 alopecia areata study by year-end 2026
  • Phase 2b ADAPTIVE topline data in atopic dermatitis expected Q4 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ImageneBio, Inc. 8-K IMA ·Originating report

Sources · 9

Hover a chip for the title
1 nasdaq.com2 markets.financialcontent.com3 sec.gov4 msn.com5 streetinsider.com6 manilatimes.net7 msn.com8 fiercebiotech.com9 healio.com